Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News?

investors.com/news/technology/biohaven-stock-fda-cancels-advisory-committee-sca-troriluzole

Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug, troriluzole.
The post Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News? appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-08-22 14:06:47.
The Entire Business World on a Single Page. Free to Use →